Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol To Sell Oncology Distribution Unit Ahead Of Medicare Part B Changes

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has signed an agreement to sell its Oncology Therapeutics Network to One Equity Partners, Bristol announces. The transaction is expected to close during the first quarter of 2005.

You may also be interested in...

Medicare “Average Sales Price” Rule Predicts $800 Mil. In Savings For 2005

CMS expects the shift from average wholesale price-based reimbursement to the ASP plus 6% formula to generate savings of $530 mil. to Medicare and $270 mil. to beneficiaries in 2005. The agency expects changes outlined in its proposed rule to bring “transparency and appropriateness” to its payments for Part B drugs.

U.S. Oncology Plans To Go Private Ahead Of Medicare Rx, But Seeking Other Bidders

The cancer care services company has worked out a $1.7 bil. buyout deal, but can actively solicit other offers until April 16. By going private, U.S. Oncology avoids wide fluctuations in its share price and possible future cuts in reimbursement.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts